Respiratory Flashcards
Diseases of the Lower Respiratory Tract? 2
What they do to the system?
Chronic obstructive pulmonary disease
Asthma (persistent and present most of the time despite treatment)
Obstruct airflow through the airways
Respiratory system:
Anatomy
Lower Respiratory Tract (trachea, bronchial tree, lungs)
URT (nose, nasopharynx, oropharynx, laryngopharynx, larynx)
4 accessory structures (oral cavity/ mouth, rib cage, muscle of ribs, and diaphragm)
Function:
gas exchange in alveoli (O2 and C02)
Filter, warm, and humidify the air
Speech, sense of smell, regualtion of pH
Bronchial Asthma
Chronic airway inflammation resulting in
bronchial constriction and hyper responsiveness to various triggers (allergen)
Recurrent and reversible shortness of breath
Occurs when the airways of the lungs become narrow
The alveolar ducts and alveoli remain open, but airflow to them is obstructed (prevents CO2 to leave and O2 in)
Bronchial Asthma occurs when the airways of the lungs become narrow as a result of: 4
Bronchospasms
Inflammation of the bronchial mucosa
Edema of the bronchial mucosa
Production of viscous mucus
Onset of asthma- before age 10 in 50% of pts and before 40 in 80% of pts
Bronchial Asthma’s alveolar ducts and alveoli remain open, but airflow to them is obstructed: What are the symptoms?5
Wheezing
Difficulty breathing
SOB
chest tightness
cough
Asthma attack
A sudden and dramatic onset
Most are short and responds to medication
status (continuing) asthmaticus
Prolonged asthma attack that does not respond to typical drug therapy
May last several minutes to hours
Medical emergency: requires hospitalization
early phase response
late phase response
mediated by antibodies already present that recognizes the antigen
Antibody for asthma- IgE
Late phase peaks 5 to 12 hours after initial response, may last for hours/ days
Chronic Obstructive Pulmonary Disease
Define& symptoms
Progressive respiratory disorder
Characterized by chronic airflow limitation, systematic manifestations, and significant comorbidities
Hypersecretion of mucus, chronic cough, and increased susceptibility to bacterial infection
Assessment of COPD
is based on symptoms, future risks of exacerbations, severity of the spirometric abnormality, and identification of comorbidities.
Chronic Bronchitis
Presence of cough and sputum for at least 3 months in each of 2 consecutive years
Separate from COPD
Focus of treatment of Lower RT
role of inflammatory cells and their mediators
Bronchodilators mechanism of action 3
Relax bronchial smooth muscle, which dilates the bronchi and bronchioles (that are narrowed)
Reduce airway constriction and restore normal airflow
Agonists, or stimulators, of the adrenergic receptors in the sympathetic nervous system
Sympathomimetics
Bronchodilators 3 CLASSES
β-adrenergic agonists
anticholinergics
xanthine derivatives
Bronchodilators:
ß-Adrenergic Agonists [sympathomimetic bronchodilators]
- Indication
- Action
- Medication (2)
Acute phase of asthmatic attacks to reduce airway constriction and restore normal airflow
Agonists/ stimulators of adrenergic R in the sympathetic NS
B agonists imitate the effects of NE and E
Short-acting: Salbutamol (SABA)
Long-acting: Salmetarol (LABA)
Bronchodilators: ß-Adrenergic Agonists [1 medication each]
Short-acting ß-agonist (SABA) inhalers
SALBUTAMOL (Ventolin®)
Terbutaline sulphate (Bricanyl®)
Long-acting ß-agonist (LABA) inhalers
formoterol (Foradil®, Oxeze®)
SALMETEROL (Serevent®)
ß-Adrenergic Agonists
LABAs are always prescribed with?
Inhaled glucocorticoids
Bronchodilators: β-Adrenergic Agonists: Newest [1 medication]
Long-acting ß-agonist and glucocorticoid steroid combination inhaler
budesonide/formoterol fumarate dihydrate (Symbicort®)
To relieve moderate to severe asthma
Bronchodilators: β-Adrenergic Agonists: budesonide/formoterol fumarate dihydrate (Symbicort®) [Indication]
Use as a reliever or rescue treatment for moderate to severe asthma when symptoms worsen
Bronchodilators: ß-Adrenergic Agonists – Three Subtypes
Nonselective adrenergic
Nonselective ß-adrenergic
Selective ß2 drugs
Bronchodilators: ß-Adrenergic Agonists:
Nonselective adrenergic
- mechanism of action
- 1 drug
- What does this stimulate?
Stimulate ß-, ß1- (cardiac), and ß2- (respiratory) receptors
Example: epinephrine (EpiPen®)
Also, stimulate a-adrenergic receptors which cause constriction within the BVs. Vasoconstriction reduces edema and swelling.
Also stimulates B1 receptors which results in cardiovascular AEs such as increased HR, force of contraction, and BP(increased renin), nervousness, tremor
Bronchodilators: ß-Adrenergic Agonists:
Nonselective ß-adrenergics
- mechanism of action
- 1 drug
Stimulate both ß1- and ß2-receptors
Example: isoproterenol hydrochloride
Bronchodilators: ß-Adrenergic Agonists:
Selective ß2 drugs
- mechanism of action
- 1 drug
- stimulates?
- Additionally treats?
- Also causes?
Stimulate only ß2-receptors
Example: salbutamol
stimulate sodium-potassium adenosine triphosphate ion pump in cell membranes, results in a temporary decrease in potassium
B2 agonists effective in treating acute hyperkalemia
Also causes uterine relaxation
ß-Adrenergic Agonists:
TWO Mechanism of Action
Dilate airways by stimulating the B2 adrenergic receptors located in lungs
Activation of ß2-receptors activates cyclic adenosine monophosphate
Increased levels of cAMP relaxes smooth muscle in the airway and results in bronchial dilation and increased airflow.
Begins at the specific receptor-stimulated. Ends with the dilation of the airways
ß-Adrenergic Agonists: Indications
Relief of bronchospasm related to asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary diseases
Used in treatment and prevention of acute attacks
Used in hypotension and shock
ß-Adrenergic Agonists: Contraindications
Known drug allergy
Uncontrolled cardiac dysrhythmias
High risk of stroke (because of the vasoconstrictive drug action)
ß-Adrenergic Agonists: Adverse Effects
Mixed α and ß (epinephrine)
Produce most AEs because they are nonselective
Mixed α and ß (epinephrine)
Insomnia
Restlessness
Anorexia
Vascular headache
Hyperglycemia
Tremor
Cardiac stimulation
ß-Adrenergic Agonists: Adverse Effects
Nonselective ß1 and ß2
Limited to B-adrenergic effects
Nonselective ß1 and ß2
Cardiac stimulation
tachycardia
Tremor
Anginal pain
Vascular headache
Overdose management
include careful admin of a B-blocker due to risk of bronshospasm
ß-Adrenergic Agonists: Adverse Effects
Selective ß2 drugs (salbutamol)
Hypotension or hypertension
Vascular headache
Tremor
ß-Adrenergic Agonists: Interactions
Diminished bronchodilation when nonselective ß-blockers are used with the ß-agonist bronchodilators
Monoamine oxidase inhibitors- HTN
Sympathomimetics - HTN
Monitor patients with diabetes; an increase in blood glucose levels can occur (esp. with epinephrine)
ß-Adrenergic Agonists:
Salbutamol Sulphate (Ventolin®)
Forms?
If used too frequently….
Short-acting ß2-specific broncho-dilating ß-agonist
Most commonly used drug in this class
Oral, parenteral, and inhalational use
Inhalational dosage forms include metered-dose inhalers as well as solutions for inhalation (aerosol nebulizers).
If used too frequently, it loses its B2 specificity: and B1 Receptors are stimulated which causes nausea, anxiety, palpitations, tremors, and increased HR
ß-Adrenergic Agonists: Salmeterol (Serevent®)
MAX DOSE
Long-acting ß2-agonist bronchodilator
Never to be used alone but in combination with an inhaled glucocorticoid steroid
Used for the maintenance treatment of asthma and COPD; salmeterol maximum daily dose (one puff twice daily) should not be exceeded
Anticholinergics [muscarinic antagonists]
Mechanism of Action
Used in the treatment of COPD
When PNS release ACh , it binds to ACh R on bronchial tree- which results in bronchial constriction and narrowing
Acetylcholine (ACh) causes bronchial constriction and narrowing of the airways.
Anticholinergics bind to the ACh receptors (block ACh R), preventing ACh from binding. Prevents constriction- indirectly causes airway dilation.
Result: bronchoconstriction is prevented, and airways dilate
Reduce secretions
Antichollinergic indication
slow and prolonged actions- used to prevent bronchospasm associated with COPD
Antichollinergic
Contraindication 3
Intercations 1
allergy
glaucoma
prostate enlargement
other antichollinergic drugs
1 MEDICATION of Anticholinergics
ipratropium (Atrovent®),
tiotropium bromide monohydrate (Spiriva®)
Antichollinergic:
Ipratropium (Atrovent®), tiotropium bromide monohydrate (Spiriva®)
Two mechanism of action
Indirectly cause airway relaxation and dilation
Help reduce secretions in COPD patients
Indications: prevention of the bronchospasm associated with COPD; not for the management of acute symptoms
oldest and most commonly used
Anticholinergics: Adverse Effects
Dry mouth or throat
Nasal congestion
Heart palpitations
Gastrointestinal distress
Urinary retention
Increased intraocular pressure
Headache
Coughing
Anxiety
can be used during pregnancy-outweighs potential risks
Anticholinergics: Ipratropium Bromide
1._____ and ____ ________ used anticholinergic bronchodilator
- Available both as a?
- Dosing?
Oldest and most commonly used anticholinergic bronchodilator
Available both as a liquid aerosol for inhalation and as a multidose inhaler
Usually dosed twice daily
Xanthine Derivatives
Consist of plant alkaloids: caffeine, theobromine, and theophylline
Only theophylline and caffeine are currently used clinically.
Synthetic xanthines: aminophylline
Xanthine Derivatives:
Mechanism of Action
What hormone do they inhibit? so that..
Causes bronchodilation by increasing the levels of energy-producing cyclic adenosine monophosphate (cAMP)
Inhibt phosphodiesterase, the enzyme that breaks down cAMP.
cAMP- maintains open airways, increased levels of cAMP leads to smooth muscle relaxation and inhibit IgE
Result: increased cAMP levels, smooth muscle relaxation, bronchodilation, and increased airflow
Xanthine Derivatives: 3Drug Effects and 1 result
Cause bronchodilation by relaxing smooth muscle in the airways
Result: relief of bronchospasm and greater airflow into and out of the lungs
Also cause central nervous system stimulation
Also cause cardiovascular stimulation: increased force of contraction and increased heart rate, resulting in increased cardiac output and increased blood flow to the kidneys (diuretic effect)
Xanthine Derivatives:
Indications
Caffeine indications
Dilation of airways in asthmas and COPD
Mild to moderate cases of acute asthma
Not for management of acute asthma attack
Adjunct drug in the management of COPD
Not used as frequently because of potential for drug interactions and variables related to drug levels in the blood
Caffeine- used without a prescription as a CNS stimulant or analeptic to promote alertness/ heart stimulant for infants IN PICU
Xanthine Derivatives: Contraindications
Known drug allergy
Uncontrolled cardiac dysthymias
Seizure disorders
Hyperthyroidism
Peptic ulcers
Xanthine Derivatives: Interactions
Increased serum level: allopurinol, cimetidine, macrolide abx (erythromycin), quinolones (cipro), influenza vaccine, rifampin, and oral contraceptives
Use with sympathomimetics/ caffeine- produce additive heart and CNS stimulation
Rifampin increases the metabolism of theophylline- and decrease theophylline levels
St. John wort- increases the rate of xanthin drug metabolism
Xanthine Derivatives: Adverse Effects
Nausea, vomiting, anorexia
Gastroesophageal reflux during sleep
Sinus tachycardia, extrasystole, palpitations, ventricular dysrhythmias
Transient increased urination
Hyperglycemia
Overdose and toxicity of xanthine derivatives are treated
repeated admin of activated charchoal
Xanthine Derivatives: Caffeine Indications 3
Used without prescription as a central nervous system stimulant or analeptic to promote alertness (e.g., for long-duration driving or studying)
Cardiac stimulant in infants with bradycardia
Enhancement of respiratory drive in infants in Neonatal Intensive Care Units (NICUs)
Xanthine Derivatives: Theophylline
Most commonly used xanthine derivative
Oral and injectable (as aminophylline) dosage forms
Aminophylline: PRODRUG of theophylline; intravenous (IV) treatment of patients with status asthmaticus who have not responded to fast-acting ß-agonists such as epinephrine
Therapeutic range for theophylline blood level is 55 to 100 mmol/L.
Canadian Asthma Consensus guideline recommends levels between 28 to 55 mmol/L.
Can also stimulate CNS (lesser degree than caffeine)
Stimulation of CNS has beneficial effects- enhance respiratory drive
In large doses, theophylline may stimulate the cardiac system- increased force of contraction (increases CO and BF to kidneys) and an increased HR (this plus xanthines ability to dilate BVs in kidneys- increases GFR- producing a diuretic effect)
Xanthine Derivatives: Theophylline
Canadian Asthma Consensus guideline recommends levels between?
28 to 55 mmol/L.
Nonbronchodilating Respiratory Drugs [3 medication]
Leukotriene receptor antagonists (montelukast, zafirlukast)
Corticosteroids (beclomethasone, budesonide, dexamethasone, flunisolide, fluticasone, ciclesonide, and triamcinolone)
Mast cell stabilizers
Mast cell stabilizers:
rarely used and no longer included in Canadian Asthma Management Continuum
Corticosteroids medication names
(beclomethasone, budesonide, dexamethasone, flunisolide, fluticasone, ciclesonide, and triamcinolone)
Leukotriene enzyme function in body
Three symptoms
causes inflammation
bronchoconstriction
mucus production
> results in coughing, wheezing, and SOB
Leukotriene Receptor Antagonists
- Type of medication
- Currently available drugs
Nonbronchodilating
Newer class of asthma medications
Currently available drugs
montelukast (Singulair®)
zafirlukast (Accolate®)
Leukotriene Receptor Antagonists:
Mechanism of Action
only affects which organ
LTRA Montelukast acts directly by binding to the D4 leukotriene-receptor subtype
Drug effects are limited primarily to the lungs
Prevents leukotrienes from attaching to receptors- this alleviates asthma symptoms and reduces inflammation. Prevent smooth muscle contraction of the bronchial airways, decrease mucus secretion, and reduce vascular permeability (reduces edema) through reducing leukotriene synthesis.
Reduce airway inflammation
Leukotriene Receptor Antagonists:
- What are Leukotrienes?
- Leukotrienes causes?
- Result?
Leukotrienes are substances released when a trigger, such as cat hair or dust, starts a series of chemical reactions in the body.
Leukotrienes cause inflammation, bronchoconstriction, and mucus production.
Result: coughing, wheezing, shortnessof breath
Leukotriene receptor antagonists prevent?
Leukotriene receptor antagonists prevent leukotrienes from attaching to receptors on cells in the lungs and in circulation.
Inflammation in the lungs is blocked, and asthma symptoms are relieved.
Leukotriene Receptor Antagonists:Drug Effects
What happens to blocking Leukotriene?
Prevent smooth muscle contraction of the bronchial airways
Decrease mucus secretion
Prevent vascular permeability
Decrease neutrophil and leukocyte infiltration to the lungs, preventing inflammation
Leukotriene Receptor Antagonists: Indications
- Indication
- Montelukast safe in children ____ years of age and older
- Zafirlukast safe in children ___ years of age and older
- Not meant for?
- Montelukast is also approved for?
- Improvement with their use is typically seen in about?
Prophylaxis and long-term treatment and prevention of asthma in adults and children
*Montelukast safe in children 2 years of age and older
*Zafirlukast safe in children 12 years of age and older
Not meant for management of acute asthmatic attacks
Montelukast is also approved for treatment of allergic rhinitis
Improvement with their use is typically seen in about 1 week
Leukotriene Receptor Antagonists: Contraindications
Known drug allergy
Previous adverse drug reaction
Allergy to povidone, lactose, titanium dioxide, or cellulose derivatives—important to note because these are inactive ingredients in these drugs
Leukotriene Receptor Antagonists: Adverse Effects
Montelukast- headache, nausea, and diarrhea (nightmare in children and adults)
Both drugs (montelukast, and zafirlukast) may lead to liver dysfunction.
zafirlukast
**Headache, nausea, diarrhea
Leukotriene Receptor Antagonists: Interaction
Phenobarbital and rifampin- are enzyme inducers, that decrease montelukast concentrations.